Page 2910 - Cote clinical veterinary advisor dogs and cats 4th

Boldface page numbers indicate chapter titles. Page numbers followed by a indicate algorithms; b, boxes; e, electronic content; f, figures; and t, tables. 1557

Scottish fold cat Selective serotonin reuptake inhibitors (SSRIs) Shar-pei (Continued)
(Continued)
hypertrophic cardiomyopathy in, 505 for separation anxiety, 906 familial amyloidosis of. See Shar-pei fever
familial nephropathy in, 169
neonatal losses in, 687
VetBooks.ir Scottish terrier Selegiline fever of unknown origin in, 334
toxicosis caused by, 71–72
osteoarthritis in, 721
food allergy in, 347
urolithiasis in, 1014
administration and dosage of, 1504
gastrointestinal lymphoma in, 604
cerebellar cortical degeneration in, 149.e3
for cognitive dysfunction, 189
hiatal hernia in, 468
and cirrhotic/fibrosing liver disease, 174 Selenium, in adulterated diets, 37t glaucoma in, 387
cutaneous neoplasia in, 230 Semduramicin, 563.e2 immunodeficiency syndrome in, 531
familial cutaneous vasculopathy in, 1031 Semen analysis, 1381–1382 intestinal adenocarcinoma in, 30
hematuria in, 428 Semen collection and evaluation intussusception in, 563.e2
lymphoma in, 609 in cats, 1161.e1–1161.e2, 1161.e2f Malassezia dermatitis in, 615
melanoma in, 644, 783.e1 description of, 542, 542f, 1072 mast cell tumor in, 634
nasal cutaneous disorders in, 676 Semen quality, brucellosis and, 138.e3 megaesophagus in, 642
paroxysmal dyskinesia in, 661 Semi-erosive polyarthritis of greyhounds, 888 nephrotic syndrome in, 691
plasma cell tumor in, 663 Seminoma, 962–963 nodular skin disorders in, 694
squamous cell carcinoma in, 939 Semintra. See Telmisartan orbital diseases in, 716
transitional cell carcinoma in, 991 Semitendinosus myopathy/contracture, 338.e2 pigmentary abnormalities in, 195
tremors/myoclonus in, 994 Senile deafness, 237 polyarthritis in, 803
vacuolar hepatopathy in, 1025 Senile tremor, 995 protein-losing enteropathy in, 600
vasculitis in, 1031.e4 Senility. See Cognitive dysfunction protein-losing nephropathy in, 2.e3, 830.e2
von Willebrand disease in, 1043 Senior pet disorders. See Geriatric disorders regurgitation in, 873
Scratching of furnishings, 115, 115.e2 Sensorineural deafness, 237 seborrhea in, 214
Screwworm, 674 Sensory ataxia, 86–87 trichiasis in, 273
Scrotal swelling, brucellosis and, 138.e3 Sensory polyneuropathies, 808–809 Shar-pei fever, 908.e2–908.e3
SDMA, 1381 Separation anxiety, 905–906 Shearing/degloving wounds, 909–911, 911.e1f
Seasonal flank alopecia. See Recurrent flank alopecia barking and, 110 Shedding, excessive. See Alopecia
Sebaceous adenitis, 214, 901–903, 902f, 903.e1f Sepsis, 907–908 Shelter/adoption-related disorders
alopecia and, 1195–1196 management of, 1448a in cats, 911.e2–911.e3
pinnal disease and, 789–790 necrotizing fasciitis and, 685 in dogs, 911.e3–911.e4
Sebaceous glands Septal defects Shetland sheepdog
dysplasia of, 216 atrial, 99.e2–99.e4, 99.e3f cutaneous lupus erythematosus in, 228
hyperplasia/adenoma of, 230–231 ventricular, 1036–1037 dermatomyositis in, 246.e2, 246.e3f, 807.e2
tumors of, 230 Septic peritonitis, 779–780, 779.e2–779.e4, 1267, 1439a Eisenmenger’s syndrome in, 288.e2
Seborrhea, 214. See also Cornification disorders Septic polyarthritis, 803–805 episcleritis/scleritis in, 304
ear margin, 790 Septic shock, 684, 907–908, 1448a facial muscle wasting in, 320
Malassezia dermatitis and, 615 Septicemia, salmonellosis and, 899 familial canine dermatomyositis in, 1032
primary idiopathic, 216 Septra. See Trimethoprim-sulfamethoxazole footpad disorders in, 350
Seborrhea oleosa, 214, 216 Sequestrum, corneal, 208–209, 208f, 725 gallbladder mucocele in, 374
Second-generation antihistamines, 73 Serax. See Oxazepam gallbladder rupture in, 375
Secondary hemostatic defects, 431, 433 Serial seizures. See Cluster seizures hyphema in, 511
Secondary hyperlipidemia, 1324 Serologic testing. See also specific diseases MDR1 mutation in, 638–639
Secondary reactive hepatopathy, 452 in abortion, 2–3 nasal cutaneous disorders in, 676
Secretin stimulation test, 382.e2 in atopic dermatitis, 92 obesity in, 700
Segmental rectal aplasia, 867.e2 Seroma, elbow. See Elbow hygroma pannus in, 748
Segmented neutrophil. See Neutrophil(s) Serotonin and norepinephrine reuptake inhibitor (SNRI) patent ductus arteriosus in, 764
Seidel test, 213 toxicosis, 71–72 pigmentary abnormalities in, 195
Seizures, 903–904 Serotonin antagonist and reuptake inhibitor, for pinnal diseases in, 789
bromethalin toxicosis and, 131 aggression, 38.e3 pneumocystosis in, 793.e2
bromide and, 1319 Serotonin syndrome, 71, 463t–464t, 736, 1281 renal tubular acidosis in, 879.e2
Brunfelsia toxicosis and, 138.e6 Sertoli cell tumor, 495.e2, 962–963 retinal detachment in, 885
causes of, 1279 Sertraline Sertoli cell tumors in, 495.e2
characteristics and differentiation of, 1280 administration and dosage of, 1504 transitional cell carcinoma in, 991
cluster, 301, 303, 904 for aggression, 39 tremors/myoclonus in, 994
epilepsy, idiopathic, 302–303 drug interactions, 111 von Willebrand disease in, 1043
focal, 302 for phobias, 788 Shiba Inu
garbage toxicosis and, 376.e3 for separation anxiety, 906 chylothorax in, 172
heat stroke and, 421 Serum, autogenous, for corneal ulceration, 210 onion or garlic toxicosis in, 707
hyperlipidemia and, 497 Serum allergen testing, for food allergy, 348 Shiga toxin-producing Escherichia coli, 431.e2
and hyperthermia, 421–422 Serum glutamic pyruvate transaminase (SGPT). See Shih tzu
metaldehyde toxicosis and, 652 Alanine aminotransferase (ALT) atopic dermatitis in, 91
refractory or poorly controlled, 1280 Serum iron. See Iron profile brachycephalic airway syndrome in, 128
strychnine toxicosis and, 946.e2 Serum proteins. See Total protein distichiasis in, 273
Selamectin, 567 Serum relaxin, 817 entropion in, 296
adverse effects of, 1510.e6t Serum urea nitrogen. See Blood urea nitrogen (BUN) familial nephropathy in, 169
for cheyletiellosis, 155 Sesamoid abnormality, 783.e1 follicular cysts in, 228.e2
drug interactions, 1510.e1t–1510.e5t Severe combined immunodeficiency syndrome, 531 keratoconjunctivitis sicca in, 569
for heartworm disease, 417, 420 Sevin, 718 Malassezia dermatitis in, 615
for nasal mites, 680.e2 Sex cord tumors, 733–734 neck pain in, 683
for otodectic mange, 731 Sex hormone abnormality. See Aberrant adrenocortical nephrolithiasis in, 689
for pediculosis, 768 disease perianal adenoma in, 31
for sarcoptic mange, 900–901 Sexual abuse, 9 portosystemic shunt in, 814
sensitivity to, MDR1 mutation and, 639 Sézary syndrome, 604.e5 pyloric outflow obstruction in, 851.e2
for tick control, 978.e3 SGPT (serum glutamic pyruvate transaminase). See renal dysplasia in, 875
toxicosis from, 567 Alanine aminotransferase (ALT) retinal detachment in, 885
Seldinger technique, 1083 Shallots, 707 stunted growth in, 946
Selective IgA deficiency, 531 Shar-pei urolithiasis in, 1014, 1014.e2, 1016, 1019
Selective serotonin reuptake inhibitors (SSRIs). See also amyloidosis in, 51–52 Shikimic acid pathway, 392
specific drugs atopic dermatitis in, 91 Shock
for aggression, 39 carpal flexural deformity in, 144–145 anaphylactic. See Anaphylaxis
for inappropriate elimination, 534 chronic vomiting in, 1042 clinical classification of, 1281.e1
for licking, excessive, 589.e2 cobalamin deficiency in, 183 hypovolemic, 911–912, 1449a
for obsessive-compulsive disorder, cutaneous neoplasia in, 230 pallor and, 736–737
702–703 enteropathies in, 1221.e1t septic, 907–908, 1448a
for phobias, 787 entropion in, 296 types of, 737
www.ExpertConsult.com